Zymeworks Inc.

ZYMESEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1937653

Concept	FY2025	FY2024	FY2023	FY2022
Revenue from Contract with Customer, Excluding Assessed Tax	$76.0M	$412.5M	$26.7M	$39.0M
Research and Development Expense	—	—	$199.8M	$171.2M
Operating Income (Loss)	-$138.1M	$130.5M	-$215.6M	-$187.5M
Nonoperating Income (Expense)	-$894.0K	$1.1M	$1.3M	$1.6M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$119.2M	$135.2M	-$212.4M	-$180.1M
Income Tax Expense (Benefit)	-$568.0K	$10.9M	-$516.0K	$429.0K
Net Income (Loss) Attributable to Parent	-$118.7M	$124.3M	-$211.8M	-$180.6M
Earnings Per Share, Basic	-$1.72	$1.91	-$4.11

Concept	FY2025	FY2024	FY2023	FY2022
Assets	$463.1M	$580.9M	$648.7M	$389.1M
Assets, Current	$300.5M	$412.9M	$544.7M	$288.2M
Cash and Cash Equivalents, at Carrying Value	$66.1M	$157.6M	$400.9M	$201.9M
Accounts Receivable, after Allowance for Credit Loss, Current	$55.8M	$19.5M	$33.4M	$15.6M
Liabilities	$124.3M	$116.1M	$155.8M	$140.0M
Liabilities, Current	$88.3M	$55.8M	$95.6M	$71.9M
Stockholders' Equity Attributable to Parent	$493.0M	$249.1M	$409.9M	$245.7M
Common Stock, Shares, Outstanding	$69.0M	$70.1M	$63.1M	$46.6M

Concept	FY2025	FY2024	FY2023	FY2022
Net Cash Provided by (Used in) Operating Activities	-$118.3M	$144.1M	-$192.5M	-$151.4M
Net Cash Provided by (Used in) Investing Activities	-$207.3M	-$53.8M	$144.6M	-$43.4M
Net Cash Provided by (Used in) Financing Activities	$81.9M	$108.6M	$8.0M	$309.0M
Payments to Acquire Property, Plant, and Equipment	$2.5M	$8.2M	$12.4M	$4.3M
Payments for Repurchase of Common Stock	$0.00	$0.00	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)